1 active not recruiting, 1 not yet recruiting. 1 Not applicable, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Not yet recruiting 1 |
Follow xiang yang: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706 - Recurrent or Metastatic Endometrial Cancer | Phase 2 | Not yet recruiting | xiang yang | 26 | 2025-02-01 | 2024-12-27 |
| Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia Methotrexate, Leucovorin, Dactinomycin - Gestational Trophoblastic Tumor, Gestational Trophoblastic Neoplasia | Not applicable | Active not recruiting | xiang yang | 228 | 2020-09-29 | 2025-08-11 |
Choriocarcinoma (1) · Endometrial Neoplasms (1) · Gestational Trophoblastic Disease (1) · Hydatidiform Mole, Invasive (1) · Recurrence (1)
Carboplatin (1) · Dactinomycin (1) · Leucovorin (1) · Methotrexate (1) · Paclitaxel (1)
China (2)